Study of semaglutide effects on insulin sensitivity and cardiometabolic risk factors confirms improvements across multiple metabolic parameters during weight management.
Key findingStudy of semaglutide effects on insulin sensitivity and cardiometabolic risk factors confirms improv
What the researchers found
Study of semaglutide effects on insulin sensitivity and cardiometabolic risk factors confirms improvements across multiple metabolic parameters during weight management.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Adolescents aged 12 to <18. Semaglutide 2.4 mg weekly vs. placebo. Estimated BMI difference: -16.7% at week 68.
How the study worked
In publication.
Who was studied
Adolescents aged 12 to <18 years with obesity
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.
Diabetes care
Citation
Arslanian, Silva; Gies, Inge; Goldman, Bryan; Karlsson, Tobias; Kelly, Aaron S; Skalshøi Kjær, Mette; Körner, Antje; Noureddin, Mazen; Wabitsch, Martin; Harder-Lauridsen, Nina M; Weghuber, Daniel. (2025). Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.. Diabetes care. https://doi.org/10.2337/dc25-0824